Instructions for Credit—There is no fee for this activity. To receive credit for this CE activity, participants must enroll in this course, review the accreditation and disclosure information, view the presentation in its entirety, successfully complete the post-activity assessment and evaluation/application for credit. If you do not achieve a minimum score of 70% on the post-activity assessment, you will be allowed to take it again. This course is accredited for up to 1.25 continuing education credits. Please retain a copy of the certificate for your records. For questions regarding the accreditation of this activity, please contact Medical Learning Institute, Inc. at (609) 333-1693 or firstname.lastname@example.org.
You must be enrolled to complete this activity for credit, however, you are not required to enroll simply to view the presentation.
Target Audience — Nurse practitioners, nurses and oncology social workers involved in the care of patients with myeloproliferative neoplasms (MPNs).
Course Content Level for Social Workers — Intermediate and Advanced
|Learning Objectives — At the conclusion of this program, participants will be able to:|
|•||Describe the types of myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia|
|•||Identify tests used to diagnose disease and monitor treatment|
|•||Explain the overarching goals of treatment for the various types of myeloproliferative neoplasms|
|•||Explain approved and emerging treatment options for myeloproliferative neoplasms including, stem cell transplantation, and the role of clinical trials|
|•||Describe strategies to manage treatment side effects as well as potential long-term and late effects of treatments|
|•||Identify resources for patients, caregivers and healthcare providers|
Provider — This activity is provided by The Leukemia & Lymphoma Society.
Continuing Education for Nurse Practitioners, Nurses, and Social Workers
Nurse Practitioner Credit Designation This activity is approved for 1.25 contact hour(s) of continuing education (which includes 1.25 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID ID 20044256. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Registered Nursing Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.25 continuing education contact hours through the California Board of Registered Nursing.
Social Worker Designation
The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved as ACE providers. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. LLS maintains responsibility for this course. ACE provider approval period: 12/10/17-12/14/2020. Social workers completing this course receive 1.25 continuing education credits.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0117. LLS maintains responsibility for this program. Social workers will receive 1.25 CE clinical contact hours for this activity.
For questions, grievances, or assistance with special needs (physical, etc.) please contact us at infocenter@LLS.org.
Disclosure of Conflicts of Interest — All faculty participating in continuing education activities by The Leukemia & Lymphoma Society are expected to disclose to activity participants any significant financial interest or other relationships with the manufacturer(s) of any commercial product(s) discussed in their presentations. The faculty are also expected to disclose any unlabeled or investigational uses of any product(s) discussed in their presentations.
Michael J. Mauro, MD
Consultant Fee: Bristol-Myers Squibb, Novartis Oncology, Pfizer, and Takeda
Research Funding: Bristol-Myers Squibb, Novartis Oncology, and Sun Pharma
Charlene Kabel, PharmD, BCOP, has no financial disclosures.
Carolanne Carini, BSN, RN, BMTCN, has no financial disclosures.
Content/Peer Reviewer Disclosures
Linda Ouyang, NP, Content/Peer Reviewer, has no financial disclosures.
Disclaimer — Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|Estimated time to complete activity: 1.25 hours|
|Date of initial release: March 27, 2020|
|Valid for CE credit through: May 31, 2021|
|Michael J. Mauro, MD, is Professor of Medicine and leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center in New York City. After receiving his BS and MD from Dartmouth College and Dartmouth Medical School in New Hampshire, he completed both residency and fellowship training at the New York-Presbyterian Hospital/Weill Cornell Medical College in Manhattan. Before joining Memorial Sloan Kettering, Dr. Mauro was on the faculty of Oregon Health and Sciences University for 13 years, where he directed the CML clinical trial program and was involved in the early development and sentinel clinical studies of ABL kinase inhibitors for CML. Dr. Mauro’s clinical expertise is in treating patients with chronic myeloid leukemia (CML) as well as other myeloproliferative disorders, including myelofibrosis, polycythemia, and thrombocytosis as well as less common conditions such as eosinophilic and mast cell disorders. He holds positions on the boards of the International CML Foundation, the MAX Foundation, and the Leukemia and Lymphoma Society.|
|Charlene Kabel, PharmD, BCOP, is a clinical pharmacy specialist on the adult leukemia service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. She graduated from Duquesne University Mylan School of Pharmacy in 2015 and completed a general first-year accredited residency at St. Joseph’s/Candler Hospital in Savannah, Georgia. In 2017, she completed a second-year specialized oncology residency at MSKCC. She serves as a Duquesne University student preceptor and second-year oncology preceptor and mentor. Her clinical research primarily focuses on optimizing therapeutic outcomes in patients diagnosed with therapy-related myeloid neoplasms and lymphoid malignancies. Dr. Kabel participated as a panel speaker for the Leukemia Lymphoma Society for family members and patients diagnosed with chronic lymphocytic leukemia (CLL).|
|Carolanne Carini, BSN, RN, BMTCN is and Oncology Nurse for 20 years, currently working as an Office Practice Nurse at Memorial Sloan Kettering Cancer Center at the new Bergen regional site in Medical Oncology with focus in myeloproliferative disorders and multiple myeloma. Her previous work experience includes 15 years of working with bone marrow transplant patients, and she obtained her certification in BMT during the inaugural year for this certification. Carolanne graduated from Georgetown University with a BSN, and she is currently pursuing a masters degree in complementary and integrative health at Drexel University. Carolanne has spent most of her career working in an outpatient center as an office practice nurse, or BMT coordinator. One of the things that Carolanne likes the best about her roles is the relationship-cased care model, working with a set team and patient population which helps to foster long term relationships.|
Resources for HCPs
Online & In-person free CME & CE courses: www.LLS.org/CE
Treating Blood Cancers podcasts: www.LLS.org/HCPpodcast
Clinical Trials and Research
- Clinical Trials: Learn more about clinical trials: LLS.org/ClinicalTrials
- Research: Focused on finding cures, driving research in areas of unmet medical need, and bridging the gap between academic discovery & drug development: LLS.org/Research
Advocacy dedicated to removing barriers to care: www.LLS.org/Advocacy
Resources for Patients
MPN Specific Resources – www.LLS.org/MPN
Free Information Booklets: www.LLS.org/Booklets
Telephone/Web Education Programs: www.LLS.org/Programs
Podcasts: www.LLS.org/LLS-podcast or TheBloodline.org
Support Resources : www.LLS.org/Support
- Financial Assistance
- Travel Assistance
- Referral to Medication Access programs
- Information Resource Center
- LLS ONLINE CHATS moderated by social workers
- LLS Chapters
- LLS Community (social media platform)
- Patti Robinson Kaufman First Connection Program (peer-to-peer)
- One-On-One Nutrition Consultations (PearlPoint)
Information Resource Specialists: www.LLS.org/PatientSupport
Help patients and caregivers learn about disease, treatments and support resources.
Clinical Trial Support Center: www.LLS.org/Navigation
Clinical Trial Nurse Navigators conduct comprehensive clinical trial searches and personally assist patients and caregivers throughout the entire clinical trial process
- Phone: (800) 955-4572, M-F, 9 am to 9 pm ET
- Email: infocenter@LLS.org
Live chat with Information Specialist: www.LLS.org/PatientSupport